Confidence in CORIFACT –
Integrated Safety System

CORIFACT is manufactured using CSL Behring's validated Integrated Safety System.

CSL Behring is dedicated to meeting high manufacturing standards for all of our products

CSL Behring’s Integrated Safety System helps the product meet high quality and safety standards.

  • Quality control measures, including numerous inspections, tests, and crosschecks, are performed by highly trained personnel at each stage in the manufacturing process.
  • All potential donors are carefully screened before being allowed to donate plasma. The plasma undergoes extensive serological and biochemical screening to minimize the risk of transmission of infectious agents, including the Creutzfeldt-Jakob disease (CJD) agent and its variant (vCJD).
Integrated Safety System

CORIFACT Manufacturing Safety

  • CORIFACT is made from pooled human plasma. The risk of virus transmission cannot be completely eliminated.
  • Specific virus inactivation and removal steps in plasma collection and the CORIFACT manufacturing process reduce the risk of exposure to infectious agents.
  • All plasma used in the manufacturing of CORIFACT is obtained from US donors, and plasma collection is rigorously monitored and controlled.
CORIFACT® Symbol

Supported by worldwide experience

CORIFACT has over 25 years of clinical experience as Fibrogammin® P outside the US.

Important Safety Information

CORIFACT®, FXIII Concentrate (Human), is indicated for routine prophylactic treatment and perioperative management of surgical bleeding in adult and pediatric patients with congenital Factor XIII deficiency. CORIFACT must be administered intravenously.

CORIFACT is contraindicated in individuals with known anaphylactic or severe systemic reactions to human plasma-derived products.

Hypersensitivity reactions may occur with CORIFACT. If there are signs of anaphylaxis or hypersensitivity reactions (including urticaria, rash, tightness of the chest, wheezing, and hypotension), immediately discontinue administration and institute appropriate treatment.

Inhibitory antibodies to FXIII have been detected in patients receiving CORIFACT. Monitor the patient’s trough FXIII activity level during treatment. If expected plasma FXIII activity levels are not attained or breakthrough bleeding occurs, perform an assay measuring FXIII inhibitory antibody concentrations.

Thromboembolic complications have been reported with CORIFACT; monitor patients with known risk factors for thrombotic events.

CORIFACT is derived from human blood. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent and its variant (vCJD), cannot be completely eliminated.

The most common adverse reactions reported in clinical trials (frequency >1%) following treatment with CORIFACT were joint inflammation, hypersensitivity, rash, pruritus; hematoma, arthralgia, headache, elevated thrombin-anti-thrombin levels, and increased blood lactate dehydrogenase. Serious adverse reactions included hypersensitivity, acute ischemia, and neutralizing antibodies against FXIII.

Please see full prescribing information for CORIFACT.

To report SUSPECTED ADVERSE REACTIONS, contact the CSL Behring Pharmacovigilance Department at 1-866-915-6958 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.